AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
Ultragenyx Pharmaceutical Inc.
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG001V2MJJ2
15.65▼ 0.30 (-1.88%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
—
Trailing P/E
—
Price / Sales
EV / Revenue
—
EV / EBITDA
—
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
—
Trading Information
Previous Close
15.95
Day's Range
15.49 – 15.94
52-Week Range
12.73 – 39.89
Volume
1.8M
Avg Volume
4.7M
Share Statistics
Shares Outstanding
Employees
1,371
Exchange
XNAS
Listed
2014-01-31
Share count as of July 31, 2026

Ultragenyx Pharmaceutical Inc. (RARE) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Ultragenyx Pharmaceutical Inc. (RARE)
What is Ultragenyx Pharmaceutical Inc.'s Market Cap?
Ultragenyx Pharmaceutical Inc.'s Market Cap is $1.5B, based on as-reported figures from SEC (XBRL) filings.
What is Ultragenyx Pharmaceutical Inc.'s Price / Sales?
Ultragenyx Pharmaceutical Inc.'s Price / Sales is 2.2×, based on as-reported figures from SEC (XBRL) filings.
What is Ultragenyx Pharmaceutical Inc.'s Revenue (TTM)?
Ultragenyx Pharmaceutical Inc.'s Revenue (TTM) is $717.0M, based on as-reported figures from SEC (XBRL) filings.
What is Ultragenyx Pharmaceutical Inc.'s Net Income (TTM)?
Ultragenyx Pharmaceutical Inc.'s Net Income (TTM) is -$586.0M, based on as-reported figures from SEC (XBRL) filings.
What is Ultragenyx Pharmaceutical Inc.'s EBITDA?
Ultragenyx Pharmaceutical Inc.'s EBITDA is -$495.0M, based on as-reported figures from SEC (XBRL) filings.
What is Ultragenyx Pharmaceutical Inc.'s Diluted EPS (TTM)?
Ultragenyx Pharmaceutical Inc.'s Diluted EPS (TTM) is -5.94, based on as-reported figures from SEC (XBRL) filings.
What is Ultragenyx Pharmaceutical Inc.'s EBITDA Margin?
Ultragenyx Pharmaceutical Inc.'s EBITDA Margin is -69.0%, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · RAREAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Revenues:
Total revenues
YoY growth+28.1%-2.2%+25.9%+14.7%
Operating expenses:
Cost of sales
Research and development
Selling, general and administrative
Total operating expenses
Loss from operations
% of revenue-35.0%-124.3%-54.7%-106.9%
Interest income
Non-cash interest expense on liabilities for sales of future royalties
Other income—
Loss before income taxes
Provision for income taxes
Net loss
% of revenue-43.0%-136.0%-62.0%-112.8%
Net loss per share, basic
Net loss per share, diluted